225 related articles for article (PubMed ID: 25167802)
21. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
Kim CH; Huh JW; Kim HR; Kim YJ
J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
[TBL] [Abstract][Full Text] [Related]
22. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
[TBL] [Abstract][Full Text] [Related]
23. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Liu Z; Yamamoto H; Loda M; Fuchs CS; Ogino S
Mod Pathol; 2008 Feb; 21(2):150-8. PubMed ID: 18084250
[TBL] [Abstract][Full Text] [Related]
24. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
25. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract][Full Text] [Related]
26. Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers.
Tapial S; Olmedillas-López S; Rueda D; Arriba M; García JL; Vivas A; Pérez J; Pena-Couso L; Olivera R; Rodríguez Y; García-Arranz M; García-Olmo D; González-Sarmiento R; Urioste M; Goel A; Perea J
Sci Rep; 2019 Jul; 9(1):10516. PubMed ID: 31324877
[TBL] [Abstract][Full Text] [Related]
27. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
29. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):585-92. PubMed ID: 17239930
[TBL] [Abstract][Full Text] [Related]
31. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype.
Nosho K; Kawasaki T; Chan AT; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Histopathology; 2008 Nov; 53(5):588-98. PubMed ID: 18983468
[TBL] [Abstract][Full Text] [Related]
33. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
[TBL] [Abstract][Full Text] [Related]
34. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.
Tanaka N; Huttenhower C; Nosho K; Baba Y; Shima K; Quackenbush J; Haigis KM; Giovannucci E; Fuchs CS; Ogino S
Am J Pathol; 2010 Dec; 177(6):2731-40. PubMed ID: 21037082
[TBL] [Abstract][Full Text] [Related]
35. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.
Kim JH; Shin SH; Kwon HJ; Cho NY; Kang GH
Virchows Arch; 2009 Dec; 455(6):485-94. PubMed ID: 19911194
[TBL] [Abstract][Full Text] [Related]
36. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.
Jo P; Jung K; Grade M; Conradi LC; Wolff HA; Kitz J; Becker H; Rüschoff J; Hartmann A; Beissbarth T; Müller-Dornieden A; Ghadimi M; Schneider-Stock R; Gaedcke J
Surgery; 2012 Apr; 151(4):564-70. PubMed ID: 22001634
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
38. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status.
Bae JM; Kim MJ; Kim JH; Koh JM; Cho NY; Kim TY; Kang GH
Virchows Arch; 2011 Jul; 459(1):55-63. PubMed ID: 21494758
[TBL] [Abstract][Full Text] [Related]
39. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
40. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
Ogino S; Nosho K; Irahara N; Meyerhardt JA; Baba Y; Shima K; Glickman JN; Ferrone CR; Mino-Kenudson M; Tanaka N; Dranoff G; Giovannucci EL; Fuchs CS
Clin Cancer Res; 2009 Oct; 15(20):6412-20. PubMed ID: 19825961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
